Document is current

Article History

Received: 9 November 2024

Revised: 12 December 2024

Accepted: 14 December 2024

First Online: 17 January 2025

Declarations

:

: M. Boaventura has received a speaker honorarium and/or travel expenses for scientific meetings from Biogen, Horizon, Amgen, AstraZeneca, Merck, Novartis and Roche and received a grant as ECTRIMS- Clinical Training fellow; D.C. Fragoso reports no disclosures relevant to the manuscript; I. Avolio reports no disclosures relevant to the manuscript; S.L.A. Pereira has received a speaker honorarium and/or travel expenses for scientific meetings from Biogen, Horizon/Amgen, Alexion, Merck, Novartis and Roche; D. Callegaro has received a speaker honorarium and/or travel expenses for scientific meetings from Biogen, Horizon, Merck, Novartis and Roche; D.K. Sato reports grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)—Brazil, grants from Fundação e Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)—Brazil, Research grants from Teva, Merck, Biogen for investigator-initiated studies and consulting fees from Merck, Roche, Horizon and Alexion.; C.C. Leite reports no disclosures relevant to the manuscript; A. Rovira serves/served on scientific advisory boards for Novartis, Sanofi- Genzyme, Icometrix, Synthetic MR, Bayer, Biogen and OLEA Medical, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche and Biogen; J.S.-Garriga has engaged in consulting and/or participating as speaker/chair in events organized by Merck, Bayer, Celgene, Sanofi and Biogen, is director of Revista de Neurología and editor for controversies of the Multiple Sclerosis Journal; D. Pareto holds a research grant from Instituto Carlos III (PI22/01709) cofunded by the European Union; C.M. Rimkus has received a grant from MSIF-ECTRIMS, speaker honoraria from Roche, Guerbet, Biogen and is associate editor of Arquivos de Neuropsiquiatria.